NEW YORK (GenomeWeb News) – MDxHealth today announced it signed agreements with health insurance providers FedMed and America's Choice Provider Network, extending access to the company's ConfirmMDx prostate cancer test to 50 million additional lives.

FedMed has 40 million covered lives, while ACPN has 11.2 million lives, MDxHealth said. The firm said that more than 130 million covered lives now have access to the ConfirmMDx test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.